No Data
No Data
Shareholder TBP of Shaanxi Kanghui Pharmaceutical (603139.SH) plans to transfer 10% of the company's shares to Sailexian at a price of 111 million yuan.
Shaanxi Kanghui Pharmaceutical (603139.SH) announced that on August 1, 2024, T..., a shareholder who holds more than 5% of the company's shares,...
Shaanxi Kanghui Pharmaceutical 2024 Semi-Annual Performance Forecast
Shaanxi Kanghui Pharmaceutical (603139.SH): Expected loss of 7 to 10 million yuan in the first half of the year.
On July 12th, Gelunhui announced that Shaanxi Kanghui Pharmaceutical (603139.SH) has released a performance forecast for the first half of 2024. According to preliminary calculations by the finance department, the company expects a net income attributable to the owner of the parent company of -10 million yuan to -7 million yuan in the first half of 2024, which will result in losses. The net income after deducting non-recurring gains and losses attributable to the owners of the parent company is expected to be -17.5 million yuan to -14.5 million yuan in the first half of 2024.
Shaanxi Kanghui Pharmaceutical (603139.SH): Received a performance compensation of 2 million yuan.
On June 11th, Gelunhui reported that Shaanxi Kanghui Pharmaceutical (603139.SH) has received the first performance compensation of 2 million yuan from Hongfu Medicine on the date of this announcement. Lansheng has not yet fully fulfilled its performance commitment compensation obligation.
Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139) Might Not Be As Mispriced As It Looks After Plunging 28%
Shaanxi Kanghui Pharmaceutical (603139.SH) has given up its priority purchase right for the equity transfer of its subsidiary.
On June 7th, Gelunhui reported that Shaanxi Kanghui Pharmaceutical Co., Ltd. (603139.SH) announced that its controlled subsidiary Shandong Youbang Biochemical Technology Co., Ltd. (referred to as 'Shandong Youbang') failed to achieve the committed performance for three consecutive years from 2021 to 2023. Original shareholder of Shandong Youbang, Lai Xinsheng, should compensate the company 269.0942 million yuan. Lai Xinsheng plans to transfer his 49% equity of Shandong Youbang to Hongfu Pharmaceutical Co., Ltd. (referred to as 'Hongfu Pharmaceutical' or 'the transferee') for a transfer price of 14.27 million yuan, of which 8.3 million yuan will be paid directly by Hongfu Pharmaceutical to the company to repay Lai Xinsheng's performance compensation, which is insufficient.
No Data